List of Excipients in Branded Drug PRESTALIA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Adhera Therapeutics Inc	PRESTALIA	perindopril arginine and amlodipine besylate	72931-010	CELLULOSE, MICROCRYSTALLINE	2029-10-05
Adhera Therapeutics Inc	PRESTALIA	perindopril arginine and amlodipine besylate	72931-010	LACTOSE MONOHYDRATE	2029-10-05
Adhera Therapeutics Inc	PRESTALIA	perindopril arginine and amlodipine besylate	72931-010	MAGNESIUM STEARATE	2029-10-05
Adhera Therapeutics Inc	PRESTALIA	perindopril arginine and amlodipine besylate	72931-010	SILICON DIOXIDE	2029-10-05

PRESTALIA Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Prestalia is a fixed-dose antihypertensive combining perindopril arginine, an ACE inhibitor, with amlodipine, a dihydropyridine calcium-channel blocker. Its commercial opportunity is concentrated in lifecycle reformulation, differentiated administration, regional generic development, and excipient supply rather than in a broad biologics-style formulation platform. The product’s existing tablet is a conventional film-coated solid oral dosage form, leaving room for patient-centric and manufacturing-focused alternatives.

What is Prestalia and which formulations are marketed?

Prestalia combines perindopril arginine and amlodipine in three strengths:

Prestalia strength	Perindopril arginine	Amlodipine
Low dose	3.5 mg	2.5 mg
Mid dose	7 mg	5 mg
High dose	14 mg	10 mg

The product is indicated for hypertension in patients whose blood pressure is inadequately controlled with perindopril or amlodipine alone, and for patients already receiving the two agents separately at the corresponding doses.[1]

Prestalia is associated with Servier and is primarily an international, particularly European, product. It is not a U.S. FDA-approved brand with a conventional Orange Book commercial position. The principal commercial markets are therefore national or regional markets where the product has received local authorization.

What dosage form does Prestalia use?

Prestalia is supplied as an immediate-release, film-coated tablet. The dosage form is designed for once-daily oral administration. The product does not rely on an extended-release matrix, gastroretentive system, enteric coating, osmotic delivery system, or specialized drug-device combination.

That profile reduces manufacturing complexity but also limits differentiation from standard generic fixed-dose combinations.

What excipients are used in Prestalia tablets?

Public product information identifies a conventional excipient system. The listed excipients include:

Component	Functional role
Lactose monohydrate	Diluent and compression aid
Microcrystalline cellulose	Filler, dry binder, and tablet-structure component
Colloidal anhydrous silica	Glidant and moisture-management aid
Magnesium stearate	Lubricant
Hypromellose	Film-forming polymer
Macrogol 6000	Coating plasticizer or coating-process aid
Glycerol	Plasticizer and coating modifier
Titanium dioxide	Opacifier and colorant

The exact excipient architecture can vary by strength, market, manufacturing site, and regulatory dossier. Commercial decisions should therefore be based on the applicable national product information and the quality module for the target market.[1]

What excipient risks are relevant to Prestalia?

The main excipient risks are not pharmacological innovation risks. They are patient-labeling, process, supply-chain, and equivalence risks.

Lactose creates a potential restriction for patients with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption. The quantity in a standard tablet is generally low, but the warning remains relevant for product positioning and label management.

Magnesium stearate can affect powder lubrication and tablet dissolution if its concentration, mixing time, or particle properties change. Colloidal silica can influence flow, blend uniformity, and moisture behavior. Hypromellose, macrogol, and glycerol affect coating performance, tablet appearance, mechanical integrity, and moisture protection.

Perindopril-containing products require particular attention to moisture and degradation control. The excipient system must support chemical stability of the active ingredients and maintain dissolution after storage. The key development variables are water activity, blend uniformity, compression force, coating weight gain, and packaging barrier performance.

Which excipient strategy is most suitable for Prestalia?

The strongest strategy is a platform approach built around three priorities: lactose reduction or elimination, improved manufacturability, and patient-centric administration.

1. Lactose-free reformulation

A lactose-free version could replace lactose monohydrate with one or more of the following:

• Mannitol
• Microcrystalline cellulose
• Dibasic calcium phosphate
• Copovidone
• Pregelatinized starch
• Spray-dried mannitol-cellulose systems
• Co-processed excipients designed for direct compression

Mannitol is commercially attractive because it supports a clean-label, low-hygroscopicity positioning and can improve mouthfeel in orally disintegrating products. Its higher cost and potentially different compaction behavior require optimization.

Dibasic calcium phosphate can improve tablet hardness and reduce sensitivity to lubrication, but its density and insolubility may complicate blend uniformity and dissolution. Copovidone can improve binding but may increase hygroscopicity. A co-processed filler-binder can reduce development time and improve high-speed compression performance.

A lactose-free formulation could support procurement diversification and a differentiated generic or line extension. It would not automatically create durable exclusivity because excipient substitutions are generally reproducible by competitors.

2. Low-moisture formulation and packaging

A low-moisture formulation could use a reduced-hygroscopicity filler system, optimized film coating, and high-barrier blister packaging. The commercial value is greatest in humid markets and in supply chains with temperature and humidity variability.

Potential packaging options include:

• Alu-Alu blister
• High-barrier PVC/PVdC blister
• HDPE bottle with desiccant
• Unit-dose hospital blistering

Packaging is often a more practical stability solution than a major excipient change. A formulation that remains stable in a lower-cost package may have greater commercial value than a technically superior formulation requiring expensive barrier materials.

3. Orally disintegrating tablet

An orally disintegrating tablet could address patients with dysphagia, older adults, and patients with difficulty swallowing conventional tablets. A development platform could use mannitol, crospovidone, low-substituted hydroxypropyl cellulose, or a co-processed orally disintegrating excipient.

The main technical risks are:

• Maintaining dose uniformity at low amlodipine loading
• Preventing segregation between the two active ingredients
• Controlling taste and mouthfeel
• Preserving perindopril stability
• Achieving rapid disintegration without excessive friability
• Managing packaging moisture sensitivity

An orally disintegrating product could support a new trademark and a limited lifecycle position, but regulatory authorities would likely require comparative dissolution and, depending on the jurisdiction and claims, additional pharmacokinetic or clinical evidence.

4. Smaller tablet and multi-strength platform

Prestalia contains three dose levels. A formulation platform using a high-functionality filler and efficient compression process could reduce tablet size or standardize tablet dimensions across strengths.

This can lower manufacturing costs and improve adherence. The commercial benefit is strongest where patients struggle with swallowing or where pharmacies and hospitals prefer a common tablet footprint.

The development challenge is maintaining content uniformity for the low-dose 3.5 mg/2.5 mg strength. A common blend may require geometric dilution, ordered mixing, or a granulation approach to control amlodipine distribution.

What formulation patents could protect a Prestalia reformulation?

The most defensible patent claims would focus on technical relationships rather than the mere presence of common excipients.

Potential claim areas include:

1. A specific ratio of perindopril arginine, amlodipine, and a low-moisture filler system.
2. A tablet with defined dissolution limits across multiple pH conditions.
3. A formulation achieving stability under accelerated humidity conditions.
4. A co-processed excipient system that improves content uniformity at the lowest strength.
5. An orally disintegrating tablet with defined disintegration time and mechanical strength.
6. A coating composition that reduces moisture ingress while preserving immediate release.
7. A packaging-formulation combination that maintains assay and impurity limits.
8. A manufacturing process using a particular granulation, blending, or compression sequence.

Broad claims to lactose-free Prestalia or the substitution of one conventional filler for another would likely face substantial obviousness and written-description challenges. Patent strength improves when the formulation demonstrates an unexpected stability, dissolution, manufacturability, or bioavailability result.

How strong is the formulation IP opportunity?

The formulation IP opportunity is moderate. The active-ingredient combination is established, and standard tablet excipients are widely known. The strongest protection would likely come from a narrow formulation patent supported by comparative data.

A practical IP package could combine:

• A composition patent for the excipient ratio
• A process patent for blend uniformity or compression
• A packaging patent or trade-secret manufacturing process
• Trademark protection for a differentiated dosage form
• Regulatory exclusivity where available

Trade secrets may be more durable than patents for blending order, granulation endpoint, coating parameters, and moisture-control specifications. They provide no protection against independent development, but they can reduce disclosure of process know-how.

What commercial opportunities exist for Prestalia excipients?

Excipient suppliers

Suppliers can target four commercial needs:

Opportunity	Relevant excipient category	Buyer value
Lactose-free tablet	Mannitol, dibasic calcium phosphate, co-processed filler	Patient-label differentiation and supply flexibility
High-speed compression	Spray-dried or co-processed direct-compression systems	Higher throughput and lower defect rates
ODT platform	Mannitol, crospovidone, low-substituted cellulose	Patient-centric dosage form
Moisture control	Low-hygroscopic excipients and barrier packaging	Improved stability and reduced returns

Co-processed excipients offer the clearest supplier opportunity because they can address flow, compactability, and content uniformity at the same time. Suppliers should support regulatory packages covering residual solvents, elemental impurities, nitrosamines where relevant, particle-size distribution, and supplier-change controls.

Generic manufacturers

Generic manufacturers can pursue three routes:

1. A conventional fixed-dose tablet closely matching the reference product.
2. A lactose-free or smaller-tablet version with limited formulation differentiation.
3. An ODT or other patient-centric product supported by a new regulatory and commercial position.

The first route has the lowest development risk and the highest price pressure. The second route can support modest differentiation. The third route offers greater pricing potential but requires more development, clinical, and regulatory investment.

Licensing opportunities

Licensing could involve:

• Regional rights to a lactose-free formulation
• An ODT technology platform
• A co-processed excipient formulation
• A high-barrier packaging system
• A manufacturing process that improves low-dose content uniformity
• A fixed-dose combination platform for other ACE inhibitor/calcium-channel blocker pairs

A licensee would likely value a package with demonstrated stability, comparative dissolution, scale-up data, and freedom-to-operate analysis more than an early-stage excipient concept.

What is the FDA and Orange Book status of Prestalia?

Prestalia does not have the profile of a U.S. Orange Book reference product. The brand is principally associated with non-U.S. markets, and no conventional U.S. Orange Book exclusivity timeline or U.S. Paragraph IV litigation pathway is central to its commercial analysis.

For a U.S. entrant, the relevant pathway would depend on whether FDA has approved a corresponding reference product and whether the proposed product qualifies for an abbreviated application. A non-U.S. Prestalia authorization does not itself establish a U.S. ANDA reference standard.

In European and other national markets, generic entry depends on local authorization rules, data exclusivity, patent records, SPCs, and national litigation. Patent and regulatory analysis must therefore be conducted country by country.

When does Prestalia lose exclusivity?

There is no single global Prestalia expiry date. Exclusivity depends on:

• The original national marketing authorization date
• Data and market exclusivity in each jurisdiction
• Composition, formulation, and use patents
• Supplementary protection certificates
• National patent-term adjustments
• Local settlement or litigation outcomes

The original fixed-dose combination and its basic tablet technology are mature. Commercial barriers are more likely to arise from country-specific formulation patents, use claims, regulatory data rights, trademarks, and manufacturing know-how than from a single globally controlling compound patent.

What generic entry risks exist for Prestalia?

Generic entry risk is high for a conventional immediate-release tablet because:

• Both active ingredients are established antihypertensive agents.
• The dosage form is conventional.
• The product has three fixed strengths that can be replicated through standard tableting.
• Common excipients are widely available.
• No complex delivery system creates a major technical barrier.

The principal barriers are regulatory equivalence, low-dose content uniformity, impurity control, stability, and local patent clearance.

A generic manufacturer may launch first with a conventional formulation and later introduce a lactose-free, smaller, or orally disintegrating version. The commercial risk to the originator is greatest in markets where substitution is automatic and reimbursement is reference-price based.

How does Prestalia compare with competing antihypertensive combinations?

Product category	Main advantage	Excipient and commercial implication
Perindopril/amlodipine	Established dual-mechanism combination	Conventional tablet is readily reproducible
Amlodipine/angiotensin-receptor blocker	Broad generic availability	Strong price competition and many suppliers
ACE inhibitor/thiazide	Long clinical history	Different tolerability and monitoring profile
Single-agent titration	Flexible dosing	Less adherence benefit than fixed-dose therapy
Triple antihypertensive therapy	Greater blood-pressure reduction potential	More complex tablet and larger formulation burden

Prestalia’s commercial advantage is adherence through fixed-dose administration and the clinical familiarity of perindopril plus amlodipine. Its weakness is limited formulation complexity, which reduces the ability to defend price through technology alone.

What patent litigation and Paragraph IV issues affect Prestalia?

No major U.S. Paragraph IV or Orange Book litigation position is central to Prestalia because the product is not primarily a U.S. Orange Book brand. In non-U.S. markets, relevant disputes would more likely involve national formulation patents, combination claims, supplementary protection certificates, or marketing authorization validity.

A complete freedom-to-operate review should examine:

• National patent registers
• European Patent Office family members
• SPC databases
• National court decisions
• Patent oppositions
• Local generic authorization records
• Any settlement or license agreements involving the fixed-dose combination

Publicly documented commercial licensing and settlement terms for Prestalia are limited. No material settlement structure should be assumed without jurisdiction-specific evidence.

Key Takeaways

• Prestalia is a conventional immediate-release fixed-dose tablet containing perindopril arginine and amlodipine.
• Its public excipient system includes lactose monohydrate, microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate, hypromellose, macrogol 6000, glycerol, and titanium dioxide.
• The strongest excipient opportunities are lactose-free reformulation, low-moisture stability, smaller tablets, and orally disintegrating tablets.
• Patent protection would be stronger for demonstrated stability, dissolution, content uniformity, or manufacturing advantages than for simple excipient substitution.
• Generic entry risk is high because the dosage form is conventional and the active ingredients are mature.
• Prestalia does not have a central U.S. Orange Book or Paragraph IV commercial framework.
• The most attractive supplier opportunity is a co-processed excipient system supporting direct compression, low-dose uniformity, and moisture control.
• National patent, regulatory, and reimbursement analysis is more important than a single global expiration date.

FAQs

Can Prestalia be reformulated without lactose?

Yes. Lactose can potentially be replaced with mannitol, dibasic calcium phosphate, starch-based binders, or co-processed direct-compression excipients. The change requires comparative stability, dissolution, manufacturability, and regulatory assessment.

Is an orally disintegrating Prestalia product commercially viable?

Yes, particularly for older patients and patients with swallowing difficulty. The main barriers are taste, moisture sensitivity, low-dose content uniformity, tablet friability, and the evidence required to support the new dosage form.

Which excipient is most important for Prestalia manufacturing?

The filler-binder system is the key development variable because it affects flow, content uniformity, tablet hardness, disintegration, and scale-up. Magnesium stearate and silica are important process aids but are less likely to provide meaningful product differentiation.

Could a Prestalia formulation patent block generic entry?

A valid formulation patent could delay or complicate entry if the generic product falls within its claims. A narrow patent directed only to a common lactose-free substitution is less likely to provide durable protection than a patent tied to unexpected stability, dissolution, or manufacturing results.

What is the best commercial positioning for a new Prestalia product?

The strongest positioning is a patient-centric, lactose-free, small-size or orally disintegrating tablet supported by demonstrated stability and improved adherence. A conventional copy would face substantially greater price competition.

References

1. Servier. (n.d.). Prestalia product information and summary of product characteristics. National and European regulatory product information.

2. European Medicines Agency. (n.d.). Guideline on quality of oral modified release products and immediate-release pharmaceutical products. European Medicines Agency.

3. European Medicines Agency. (2019). Guideline on the investigation of bioequivalence. European Medicines Agency.

4. U.S. Food and Drug Administration. (2016). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA.

5. International Council for Harmonisation. (2003). ICH Q8(R2): Pharmaceutical development. ICH.

6. International Council for Harmonisation. (2009). ICH Q9: Quality risk management. ICH.

7. International Council for Harmonisation. (2009). ICH Q10: Pharmaceutical quality system. ICH.